Baseline characteristics of patients receiving anticoagulation for LV thrombus
| Overall (n=20) | VKA (n=4) | DOAC (n=14) | LMWH (n=2) | |
| Demographics | ||||
| Age | 60.9±11.5 | 63.5±5.4 | 58.5±12.6 | 70.5±9.2 |
| Male sex | 17 (85) | 3 (75) | 12 (85.7) | 2 (100) |
| White-European ethnicity | 18 (90) | 4 (100) | 12 (85.7) | 2 (100) |
| Comorbidities | ||||
| Diabetes mellitus | 6 (30) | 1 (25) | 3 (21) | 2 (100) |
| Atrial fibrillation | 3 (15) | 1 (25) | 1 (7) | 1 (50) |
| Hypertension | 5 (25) | 0 (0) | 4 (29) | 1 (50) |
| Peripheral vascular disease | 1 (5) | 0 (0) | 1 (7) | 0 (0) |
| Stroke/TIA | 2 (10) | 1 (25) | 1 (7) | 0 (0) |
| PE/DVT | 1 (10) | 0 (0) | 1 (7) | 1 (50) |
| Smoking history | 10 (50) | 1 (25) | 1 (7) | 1 (50) |
| Aetiology | ||||
| Ischaemic | 14 (70) | 1 (25) | 11 (79) | 2 (100) |
| Dilated cardiomyopathy | 3 (15) | 1 (25) | 2 (7) | 0 (0) |
| Myocarditis | 2 (10) | 1 (25) | 1 (7) | 0 (0) |
| Antiplatelet therapy | ||||
| Aspirin | 8 (40) | 1 (25) | 6 (30) | 1 (50) |
| P2Y12 inhibitor | 10 (50) | 2 (50) | 8 (57) | 0 (0) |
DOAC, direct oral anticoagulants; DVT, Deep vein thrombosis; LMWH, low-molecular-weight heparin; LV, left ventricular; PE, Pulmonary embolism; TIA, Transient ischaemic attack; VKA, vitamin K antagonists.